India says current IPR norms sufficient to 'checkmate' evergreening
This article was originally published in Scrip
India's department of industrial policy and promotion (DIPP) has rebuked suggestions put forth by large multinational companies (MNCs) on the need to tweak Indian patent legislation, especially provisions concerning incremental inventions.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.